M16-560 Primary Analyses of the Primary Endpoint

Two primary comparisons were performed between ABBV-3373 and adalimumab. The first was the comparison of ABBV-3373 to historical adalimumab reference value -2.13 based on a meta-analysis consisting of 242 subjects from 3 historical adalimumab studies in which the success criterion was 2-sided P value 0.1.

Primary Comparison 1: Compare ABBV-3373 to a Historical Reference Value of Adalimumab

Change from Baseline in DAS28(CRP) at Week 12 (MMRM)(CC)

					(Full Analysis Set)							
		Change from Baseline										
					Within Group#	Compare to Historical Adalimumab Data@						
Par amet er Tr eat ment	N	Baseline Mean	Visit Mean	LS Mean	[90% CI]	SE	LS Mean	[90% CI]	SE	P- val ue		
DI SEASE ACTI VI TY SCORE BA	SED	ON CRP										
Adal i mumab 80 mg SC EOM ABBV-3373 100 mg I V EOM		5. 60 5. 49	2. 88 2. 78	- 2. 51 - 2. 65	[-3.00, -2.02] [-3.01, -2.29]	0. 293 0. 215	- 0. 52	[-0.89, -0.15]	0. 215	0. 022+		

Note: Baseline is defined as the last non-missing value prior to the first dose of study drug. Subjects with non-missing baseline and at least one post-baseline value is included in the analyses.

the combined mean change from Baseline in adalimumab was 2.29.

Primary Comparison : Compare ABBV-3373 to Adalimumab

Change from Baseline in DAS28(CRP) at Week 12 Using Bayesian Historical Borrowing-Fixed Borrowing of 30 Historical Adalimumab Patients
Borrowed (OC)
(Full Analysis Set)

	Within Group - Change from Baseline -			Between Groups Difference Compared to Adalimumab (Posterior) P(Posterior Bayesia				
Parameter Treatment / (Data Source)	N	Mean	SE	Mean	[90% Credible Interval]	SE	Treatment Difference < 0)	Success (>0.95)
DISEASE ACTIVITY SCORE BASED ON CRP Adalimumab 80 mg SC EOW (In trial)	16	-2.51	0.293					
Adalimumab 80 mg SC EOW (Prior/Historical)	30	-2.13	0.246					
Adalimumab 80 mg SC EOW (Posterior)		-2.29	0.189					
ABBV-3373 100 mg IV EOW (In trial)	29	-2.65	0.215	-0.37	[-0.84, 0.11]	0.286	0.899	N

Note: The mean within group for data source in trial is the least square mean from ABBV-3373 and Adalimumab estimated by MMRM model including up to week 12 data with unstructured variance-covariance matrix, including treatment, visit, stratification factors, and treatment-by-visit interaction as fixed factors and baseline value as covariate.

Baseline is defined as the last non-missing value prior to the first dose of study drug. Subjects with non-missing baseline and at least one post-baseline value is included in the analyses.

[#] Within group least squares mean and 90% confidence interval are based on mixed effect model repeated measurement (MMRM) Analysis with unstructured variance-covariance matrix, including treatment, visit, stratification factors, and treatment-by-visit interaction as fixed factors and baseline value as covariate.

[@] Single-arm comparison of LS mean of ABBV-3373 estimated from the MMRM model above with Historical mean of Adalimumab (-2.13).